UNIVERSITY CITY, January 15, 2020 / PRNewswire / – USA Newsgroup – A new study published in the journal Molecular Therapy reports that drug researchers used to treat HIV could also have a Zika virus infection. Zika virus disease is caused by a virus that transmits mainly Aedes mosquitoes, which is believed during the day.
Research and developments with a multidisciplinary approach are critical to the treatment and protection of viral and infectious diseases as they become more aggressive and finer. Companies who are preparing to offer new treatments to deal with the attack could be a valuable part in the next decade. Leaders in this space look forward to a strong income from co-workers including NGM Biopharmaceuticals Inc. (NASDAQ: NGM), Emergent BioSolutions Inc. (NYSE: EBS), and SIGA Technologies, Inc. (NASDAQ: SIGA)
One unknown relationship in space is Dullon Medical, Inc., a medical technology company, which aims to address unmet needs worldwide. Aethlon Medical Inc. (NASDAQ: AEMD) The developer of the Paten Hemopurifier Aethlon, is a clinical therapeutic immunization device extracted from exosomes and viruses that are life-threatening from the human circulatory system. This device can be widely used to combat very infectious diseases such as Ebola virus. Dullon is developing TauSome, an exosomal bioaccumulation candidate also to diagnose chronic traumatic diagnosis in live people.
Focus on two viruses simultaneously
The new rilpivirine drug was shown in the new study using cell and animal models to stop the Zika virus by focusing on enzymes dependent on HIV and Zika virus to replicate them. These enzymes also occur in a larger group of viruses considered to be closely related to Zika. These are the viruses known to cause dignity, yellow fever, West Nile fever, and hepatitis C.
Kamel Khalili, PhD, Laura H. Carnell Professor and Chair of the Department of Neuroscience, Director of the Neuropsychology Center, and Director of Comprehensive NeuroAIDS Center at LKSOM, "Virus HIV and Zika says of specific types of RNA viruses. Zika virus replication is linked by RNA polymerase enzyme is common to a family of RNA viruses, which we opened the way to be able to treat multiple RNA virus infections using the same strategy. "
Zika virus requires an enzyme called RNA 5-RSA-dependent non-structural polymer (NS5 RdRp) to replicate inside cells. One of the researchers in the new study showed that rilpivirine causes Zika virus infection in cells by restricting viral replication, which makes Zika unused. The researchers hired structural and computational biology studies to show that rilpivirine prevents viral replication by specifically linking domains NS5.
The transmission of multiple viruses as Protection
The approach in the study is one of the many areas where biotech companies are innovating over viruses. This could mean turning technologies or finding novel treatments such as approaches Didlon Medical Inc., which was unveiled in 2014, Aethlon Medical is developing its Hemopurifier® – the most protected therapeutic devices. in the world.
This unique blood purification device is a world-class therapeutic technology which receives two FDA Breakdown specifications, through multiple therapeutic targets: viral disease and cancer.
To date, Hemopurifier® therapy has been given to individuals infected with Ebola virus, Hepatitis C virus (HCV) and the Human Immunodeficiency (HIV) virus. In the case of Ebola, it was through a "fantastic response" to the Hemopurifier® therapy of reciprocal patients (Uganda doctor) who had multiple failure at the time given by Time Magazine awards.
Apart from human treatment experiences, preliminary clinical Hemopurifier® studies gathered the array of spectrum of viral threats, including: Chikungunya, Dengue and West Nile virus, Vaccinia and Monkey vaccine, human infection infection models. Since he was named FDA's “Breakdown Device”, Hemopurifier® therapies have focused on his role in fighting cancer in the cases of chemotherapy resistance, metastasis promotion, and immunosuppression.
Way to Start to Deal with Fatal Viruses
It is clear from researchers that the approaches being proposed are a way forward with viruses and infectious diseases. And there is a good reason to look out for a real outcome in treatment. Epidemics associated with flavivirus infections, particularly HIV, Zika, dengue, and hepatitis C often go on a geographical and time-consuming basis. "These potential applications are associated with this huge work," the researchers suggested.
"We now have a clear path," said Dr. T Khalili. "We have a starting point from which we can find ways to make these drugs stronger and more effective against flaviviruses."
Word is the researchers who will intensify their studies to develop ways of improving the effectiveness of NNRTIs in preventing infection with Zika virus and other flaviviruses. This can only be used by therapists and drugs developers who will protect wider infections. Companies in the biotechnology space that could benefit from the emergence and treatment of virus-based diseases include: t
NGM Biopharmaceuticals Inc. (NASDAQ: NGM) it is a biopharmaceutical company that promotes a strong pipeline for drug candidates to address a spectrum of major medical needs that are not being met. They are aimed at harnessing unused power biology, which forms the basis for the development of changing therapies for patients.
BioSolutions Incgent (NYSE: EBS) It is a life sciences company aiming to provide specialty products to civilian and military populations that accidentally address public health threats (PHTs), deliberately and naturally occurring. Its products address PHTs, including chemicals, biological, radiological, nuclear and explosives; emerging infectious diseases; travelers' diseases; and opioids. BiSolutions recently reported that her $ 2 billion government contract to provide smallpox vaccines. Analysts note that our government is still vigilant about its people and its military to protect biological threats and that it continues to buy stock like vaccines to ensure that they are prepared.
SIGA Technologies, Inc. (NASDAQ: SIGA) It is a commercial stage pharmaceutical company focusing on the health security markets in Ireland the United States. Its main product is TPOXX, an oral administered antivirus drug for the treatment of human disease caused by variola virus. The company was established in 1995 and has its headquarters in the year New York, New York. SIGA recently announced that the Canadian National Defense Department (NACD) issued a high contract award notice (ACAN), indicating that it intends to award a contract to fund regulatory filing with Health Canada to allow oral TPOXX® .
For more information on biotechnology developments and the markets that provide solutions, see the report USA Newsgroup: https://usanewsgroup.com/2020/01/03/could-this-fda-designated-break.htm-eas–comhlacht-save-the-world-from-a-threat-that-could-wipe-out -millions- people-in-hours /
Article Source: t
Legal Disclaimer / Disclosure:
This is an advertisement notice and was paid for. This document is not being offered as a tender for a sale or offer to purchase or subscribe any investment, and should not be construed as an offer. No information in this Report should be construed as a single investment council. A licensed financial adviser should be consulted before any investment decision is made. We do not guarantee, represent or warrant and accept no responsibility or liability for its accuracy or completeness. The opinion of the US News Group is only comments and can be changed without notice. The USA News Group accepts no warranty, liability or guarantee for the materiality, accuracy or completeness of the information currently provided in this Report and shall not be liable for reliance on any existing or no opinion or statement. deficit. In addition, we do not accept any liability for any direct or indirect loss or damage or, in particular, for lost profits, which you may incur as a result of the use and existence of the information provided in this Report.
DISCLAIMER: USA The source material listed above is the Source News Group. FN Media Group, LLC (FNM), and a news distribution service provider, disseminates electronic information via online media channels. NO FNM is affiliated in any way to US Newsgroup or any company mentioned here. The comments, views and opinions expressed by the USA News Group in this release are those which are contained in the USA News Group only and are not shared by or reflect in any way the views or opinions of FNM. FNM is not liable for any investment decisions made by its readers or subscribers. The FNM and its affiliated companies are a dispersed news provider and financial marketing solutions and are not a registered broker / dealer / analyst / consultant, do not hold investment licenses and cannot sell, offer for sale or offer any security. No public company mentioned here compensated the FNM for the dissemination of this press release.
NO COMPANY IS NON-TERMED BY ANY COMPANY NOMINATED IN THIS EXAMINATION.
This statement contains "forward-looking statements" within the meaning of Section 27A of the Securities Act, 1933, as amended, and Section 21E of the Securities Exchange Act 1934, as amended and makes such forward-looking statements pursuant to the safe harbor the provisions of the Private Litigation Reform Act 1995. “Looking forward statements” describe future expectations, plans, outcomes or strategies and typically words such as "may", "future", "plan" or "planned" before them. , "will" or "should", "expect," "expect", "draft", "in the end" or "projected". You are warned that these statements are subject to many risks and uncertainties that may give rise to circumstances, events or future results being different from those envisaged in the statements that are t forward-looking, including the risks that actual outcomes may differ materially from the projected outcomes in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10 -K or 10-KSB and on another filing made by that company with the Securities and Exchange Commission. You should consider these factors and consider the forward looking statements included here, and not unduly rely on such statements. The emerging statements in this release are from this date and there is no obligation on the FNM to update these statements.
Media Contact Information:
FN Media Group, LLC
Media contact email:
Phone.s. Phone: +1(954)345-0611
See original content: hiv-west-nile-and smallpox-wins-tall-naming-breakthrough-device-300987254.html
SOURCE USA Newsgroup